Therapeutic effects of XPO1 inhibition in thymic epithelial tumors

Fabio Conforti, Xu Zhang, Guanhua Rao, Tommaso De Pas, Yoko Yonemori, Jose Antonio Rodriguez, Justine N. McCutcheon, Raneen Rahhal, Anna T. Alberobello, Yisong Wang, Yu Wen Zhang, Udayan Guha, Giuseppe Giaccone

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Exportin 1 (XPO1) mediates nuclear export of many cellular factors known to play critical roles in malignant processes, and selinexor (KPT-330) is the first XPO1-selective inhibitor of nuclear export compound in advanced clinical development phase for cancer treatment. We demonstrated here that inhibition of XPO1 drives nuclear accumulation of important cargo tumor suppressor proteins, including transcription factor FOXO3a and p53 in thymic epithelial tumor (TET) cells, and induces p53-dependent and -independent antitumor activity in vitro. Selinexor suppressed the growth of TET xenograft tumors in athymic nude mice via inhibition of cell proliferation and induction of apoptosis. Loss of p53 activity or amplification of XPO1 may contribute to resistance to XPO1 inhibitor in TET. Using mass spectrometry–based proteomics analysis, we identified a number of proteins whose abundances in the nucleus and cytoplasm shifted significantly following selinexor treatment in the TET cells. Furthermore, we found that XPO1 was highly expressed in aggressive histotypes and advanced stages of human TET, and high XPO1 expression was associated with poorer patient survival. These results underscore an important role of XPO1 in the pathogenesis of TET and support clinical development of the XPO1 inhibitor for the treatment of patients with this type of tumors.

Original languageEnglish
Pages (from-to)5614-5627
Number of pages14
JournalCancer Research
Volume77
Issue number20
DOIs
Publication statusPublished - Oct 15 2017

Fingerprint

Therapeutic Uses
Cell Nucleus Active Transport
Nude Mice
Epithelial Cells
Tumor Suppressor Proteins
Neoplasms
Heterografts
Proteomics
Thymic epithelial tumor
Cytoplasm
Transcription Factors
Therapeutics
Cell Proliferation
Apoptosis
Survival
KPT-330
Growth
Proteins

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Conforti, F., Zhang, X., Rao, G., De Pas, T., Yonemori, Y., Rodriguez, J. A., ... Giaccone, G. (2017). Therapeutic effects of XPO1 inhibition in thymic epithelial tumors. Cancer Research, 77(20), 5614-5627. https://doi.org/10.1158/0008-5472.CAN-17-1323

Therapeutic effects of XPO1 inhibition in thymic epithelial tumors. / Conforti, Fabio; Zhang, Xu; Rao, Guanhua; De Pas, Tommaso; Yonemori, Yoko; Rodriguez, Jose Antonio; McCutcheon, Justine N.; Rahhal, Raneen; Alberobello, Anna T.; Wang, Yisong; Zhang, Yu Wen; Guha, Udayan; Giaccone, Giuseppe.

In: Cancer Research, Vol. 77, No. 20, 15.10.2017, p. 5614-5627.

Research output: Contribution to journalArticle

Conforti, F, Zhang, X, Rao, G, De Pas, T, Yonemori, Y, Rodriguez, JA, McCutcheon, JN, Rahhal, R, Alberobello, AT, Wang, Y, Zhang, YW, Guha, U & Giaccone, G 2017, 'Therapeutic effects of XPO1 inhibition in thymic epithelial tumors', Cancer Research, vol. 77, no. 20, pp. 5614-5627. https://doi.org/10.1158/0008-5472.CAN-17-1323
Conforti, Fabio ; Zhang, Xu ; Rao, Guanhua ; De Pas, Tommaso ; Yonemori, Yoko ; Rodriguez, Jose Antonio ; McCutcheon, Justine N. ; Rahhal, Raneen ; Alberobello, Anna T. ; Wang, Yisong ; Zhang, Yu Wen ; Guha, Udayan ; Giaccone, Giuseppe. / Therapeutic effects of XPO1 inhibition in thymic epithelial tumors. In: Cancer Research. 2017 ; Vol. 77, No. 20. pp. 5614-5627.
@article{42fe84ad2b0e4ae5920b64b3c03ee617,
title = "Therapeutic effects of XPO1 inhibition in thymic epithelial tumors",
abstract = "Exportin 1 (XPO1) mediates nuclear export of many cellular factors known to play critical roles in malignant processes, and selinexor (KPT-330) is the first XPO1-selective inhibitor of nuclear export compound in advanced clinical development phase for cancer treatment. We demonstrated here that inhibition of XPO1 drives nuclear accumulation of important cargo tumor suppressor proteins, including transcription factor FOXO3a and p53 in thymic epithelial tumor (TET) cells, and induces p53-dependent and -independent antitumor activity in vitro. Selinexor suppressed the growth of TET xenograft tumors in athymic nude mice via inhibition of cell proliferation and induction of apoptosis. Loss of p53 activity or amplification of XPO1 may contribute to resistance to XPO1 inhibitor in TET. Using mass spectrometry–based proteomics analysis, we identified a number of proteins whose abundances in the nucleus and cytoplasm shifted significantly following selinexor treatment in the TET cells. Furthermore, we found that XPO1 was highly expressed in aggressive histotypes and advanced stages of human TET, and high XPO1 expression was associated with poorer patient survival. These results underscore an important role of XPO1 in the pathogenesis of TET and support clinical development of the XPO1 inhibitor for the treatment of patients with this type of tumors.",
author = "Fabio Conforti and Xu Zhang and Guanhua Rao and {De Pas}, Tommaso and Yoko Yonemori and Rodriguez, {Jose Antonio} and McCutcheon, {Justine N.} and Raneen Rahhal and Alberobello, {Anna T.} and Yisong Wang and Zhang, {Yu Wen} and Udayan Guha and Giuseppe Giaccone",
year = "2017",
month = "10",
day = "15",
doi = "10.1158/0008-5472.CAN-17-1323",
language = "English",
volume = "77",
pages = "5614--5627",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "20",

}

TY - JOUR

T1 - Therapeutic effects of XPO1 inhibition in thymic epithelial tumors

AU - Conforti, Fabio

AU - Zhang, Xu

AU - Rao, Guanhua

AU - De Pas, Tommaso

AU - Yonemori, Yoko

AU - Rodriguez, Jose Antonio

AU - McCutcheon, Justine N.

AU - Rahhal, Raneen

AU - Alberobello, Anna T.

AU - Wang, Yisong

AU - Zhang, Yu Wen

AU - Guha, Udayan

AU - Giaccone, Giuseppe

PY - 2017/10/15

Y1 - 2017/10/15

N2 - Exportin 1 (XPO1) mediates nuclear export of many cellular factors known to play critical roles in malignant processes, and selinexor (KPT-330) is the first XPO1-selective inhibitor of nuclear export compound in advanced clinical development phase for cancer treatment. We demonstrated here that inhibition of XPO1 drives nuclear accumulation of important cargo tumor suppressor proteins, including transcription factor FOXO3a and p53 in thymic epithelial tumor (TET) cells, and induces p53-dependent and -independent antitumor activity in vitro. Selinexor suppressed the growth of TET xenograft tumors in athymic nude mice via inhibition of cell proliferation and induction of apoptosis. Loss of p53 activity or amplification of XPO1 may contribute to resistance to XPO1 inhibitor in TET. Using mass spectrometry–based proteomics analysis, we identified a number of proteins whose abundances in the nucleus and cytoplasm shifted significantly following selinexor treatment in the TET cells. Furthermore, we found that XPO1 was highly expressed in aggressive histotypes and advanced stages of human TET, and high XPO1 expression was associated with poorer patient survival. These results underscore an important role of XPO1 in the pathogenesis of TET and support clinical development of the XPO1 inhibitor for the treatment of patients with this type of tumors.

AB - Exportin 1 (XPO1) mediates nuclear export of many cellular factors known to play critical roles in malignant processes, and selinexor (KPT-330) is the first XPO1-selective inhibitor of nuclear export compound in advanced clinical development phase for cancer treatment. We demonstrated here that inhibition of XPO1 drives nuclear accumulation of important cargo tumor suppressor proteins, including transcription factor FOXO3a and p53 in thymic epithelial tumor (TET) cells, and induces p53-dependent and -independent antitumor activity in vitro. Selinexor suppressed the growth of TET xenograft tumors in athymic nude mice via inhibition of cell proliferation and induction of apoptosis. Loss of p53 activity or amplification of XPO1 may contribute to resistance to XPO1 inhibitor in TET. Using mass spectrometry–based proteomics analysis, we identified a number of proteins whose abundances in the nucleus and cytoplasm shifted significantly following selinexor treatment in the TET cells. Furthermore, we found that XPO1 was highly expressed in aggressive histotypes and advanced stages of human TET, and high XPO1 expression was associated with poorer patient survival. These results underscore an important role of XPO1 in the pathogenesis of TET and support clinical development of the XPO1 inhibitor for the treatment of patients with this type of tumors.

UR - http://www.scopus.com/inward/record.url?scp=85031426542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031426542&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-17-1323

DO - 10.1158/0008-5472.CAN-17-1323

M3 - Article

VL - 77

SP - 5614

EP - 5627

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 20

ER -